$BioCardia(BCDA.US)$BioCardia Completes Enrollment of Cardiamp Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-in Cohort
BioCardia, Inc. (NASDAQ: $BCDA), a leader in the field of regenerative biotechnology. In a groundbreaking move, BioCardia, Inc. (NASDAQ: $BCDA), a leader in the field of regenerative biotechnology, has announced a strategic partnership with StemCardia, Inc., a cutting-edge stem cell therapy company. This alliance is set to revolutionize the delivery of biotherapeutics, potentially reshaping the future of regenerative medicine.$BioCardia(BCDA.US)$ ...
BioCardia's CardiAMP Cell Therapy: A Groundbreaking Development in Heart Failure Treatment. In a significant development for the field of cardiovascular disease treatment, BioCardia, Inc. (NASDAQ: BCDA), a leader in innovative, autologous cell therapies, announced the Centers for Medicare & Medicaid Services (CMS) approval for its CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study. This breakthrough has the po...
$BioCardia(BCDA.US)$BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study 3 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE
$BioCardia(BCDA.US)$BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure 2 MINUTES AGO, 8:00 AM EST VIA GLOBENEWSWIRE
$BioCardia(BCDA.US)$04 March 2024 new data from phase 3 and phase 1/2 trials will be presented at the Technology and Heart Failure Therapeutics Conference.
BioCardia股票討論區
Update
🎯 Ph 3 readouts in Q2 2024...
$CG Oncology(CGON.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$美國聯合醫療(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
Biotech Stock Catalyst Watchlist
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黃醫藥(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
Biotherapeutics Delivery Partnership Announced By Biotech Company
In a groundbreaking move, BioCardia, Inc. (NASDAQ: $BCDA), a leader in the field of regenerative biotechnology, has announced a strategic partnership with StemCardia, Inc., a cutting-edge stem cell therapy company. This alliance is set to revolutionize the delivery of biotherapeutics, potentially reshaping the future of regenerative medicine. $BioCardia(BCDA.US)$
...
Cell Therapy Company Announces Approval For Heart Failure Treatment Study
In a significant development for the field of cardiovascular disease treatment, BioCardia, Inc. (NASDAQ: BCDA), a leader in innovative, autologous cell therapies, announced the Centers for Medicare & Medicaid Services (CMS) approval for its CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study. This breakthrough has the po...
Update
3 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE
News
2 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
🎯 Ph 3 readouts in Q1 2024...
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Crinetics(CRNX.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$ Phase 3
$Aquestive Therapeutics(AQST.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phase 3
$Novocure(NVCR.US)$ Phase 3
$強生(JNJ.US)$ Phase 3
Biotech Stock Catalyst Watchlist
$輝瑞(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood醫藥(IRWD.US)$ Phase 3
$阿里拉姆制藥(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$羅氏(ADR)(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$阿卡迪亞(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...
暫無評論